Premium
Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi‐institutional retrospective analysis in 52 patients
Author(s) -
Valle M.,
Van der Speeten K.,
Garofalo A.
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21321
Subject(s) - medicine , ascites , hyperthermic intraperitoneal chemotherapy , chemotherapy , refractory (planetary science) , intraperitoneal chemotherapy , surgery , laparoscopy , cancer , general surgery , cytoreductive surgery , ovarian cancer , physics , astrobiology
Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment‐related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites. J. Surg. Oncol. 2009;100:331–334. © 2009 Wiley‐Liss, Inc.